In this case the Commercial Court lifts an ex parte preliminary injunction against the launch of several generics of Pramipexol after an inter partes hearing. The ex parte decision was grounded on a Supplementary Protection Certificate based on a patent granted under the 1929 Patents Act. One of the claims of the patent was construed as conferring de facto protection on the product. As to this de facto protection the Commercial Court considered that, although the scope of protection of patents granted under the 1929 Patents Act must be determined according to the 1986 Patents Act (interpreting the claims in the context of the specification), one must take into account that under the 1929 Patents Act omnibus claims were included for formal reasons. Hence they cannot be interpreted as conferring de facto protection on the product.

The full summary of this case has been published on Kluwer IP Law.


To make sure you do not miss out on regular updates from the Kluwer Patent Blog, please subscribe here.

Kluwer IP Law

The 2022 Future Ready Lawyer survey showed that 79% of lawyers think that the importance of legal technology will increase for next year. With Kluwer IP Law you can navigate the increasingly global practice of IP law with specialized, local and cross-border information and tools from every preferred location. Are you, as an IP professional, ready for the future?

Learn how Kluwer IP Law can support you.

Kluwer IP Law
This page as PDF